Esperion to Participate in Fireside Chat at the UBS Global Healthcare Conference
May 19 2017 - 4:30PM
Fireside Chat Webcast on Tuesday,
May 23, 2017 at 9:00 a.m. Eastern Time
Esperion Therapeutics, Inc. (NASDAQ:ESPR), the Lipid Management
Company focused on developing and commercializing convenient,
complementary, cost-effective, once-daily, oral therapies for the
treatment of patients with elevated low density lipoprotein
cholesterol (LDL-C), today announced that president and chief
executive officer, Tim M. Mayleben, will participate in an
analyst-led fireside chat with investors at the UBS Global
Healthcare Conference in New York City on Tuesday, May 23, 2017 at
9:00 a.m. Eastern Time.
A live audio webcast of this event can be accessed on the
investor relations section of the Esperion website
at www.esperion.com. Replay of the webcast will be archived on
the Company's website for 90 days following the event.
Bempedoic Acid
With a targeted mechanism of action, bempedoic acid is a
first-in-class, orally available, once-daily ACL inhibitor that
reduces cholesterol biosynthesis and lowers elevated levels of
LDL-C by up-regulating the LDL receptor, and may potentially be
associated with a lower occurrence of muscle-related side effects.
Completed Phase 1 and 2 studies in more than 800 patients treated
with bempedoic acid have produced clinically relevant LDL-C
lowering results of up to 30 percent as monotherapy, approximately
50 percent in combination with ezetimibe, and an incremental 20+
percent when added to stable statin therapy.
Esperion's Commitment to Patients with
Hypercholesterolemia
In the United States, 78 million people, or more than 20 percent
of the population, have elevated LDL-C; an additional 73 million
people in Europe and 30 million people in Japan also live with
elevated LDL-C. Esperion's mission as the Lipid Management Company
is to provide patients and physicians with convenient,
complementary, cost-effective, once-daily, oral therapies to
significantly reduce elevated levels of LDL-C in patients
inadequately treated with current lipid-modifying
therapies. It is estimated that 40 million patients in the
U.S. are taking statins with approximately 5-20 percent of
these patients only able to tolerate less than the lowest approved
daily starting dose of their statin and considered statin
intolerant. Esperion-discovered and developed, bempedoic acid is a
targeted LDL-C lowering therapy in Phase 3 development. The Company
has two Phase 3 products in development: 1) bempedoic acid
(monotherapy) an oral, once-daily pill, and 2) an, oral, once-daily
fixed dose combination pill of bempedoic acid and ezetimibe
(BA+EZ).
The Lipid Management Company
Esperion Therapeutics, Inc. is the Lipid Management Company
passionately committed to developing and commercializing
convenient, complementary, cost-effective, once-daily, oral
therapies for the treatment of patients with elevated LDL-C.
Through scientific and clinical excellence, and a deep
understanding of cholesterol biology, the experienced lipid
management team at Esperion is committed to developing new LDL-C
lowering therapies that will make a substantial impact on reducing
global CVD; the leading cause of death around the world. Bempedoic
acid, the Company's lead product candidate, is a targeted therapy
that has been shown to significantly reduce elevated LDL-C levels
in patients with hypercholesterolemia, including patients
inadequately treated with current lipid-modifying therapies. For
more information, please visit www.esperion.com and
follow us on Twitter at https://twitter.com/EsperionInc.
Media Contact:
Elliot Fox
W2O Group
212.257.6724
efox@w2ogroup.com
Investor Contact:
Mindy Lowe
Esperion Therapeutics, Inc.
734.887.3903
mlowe@esperion.com
Esperion Therapeutics (NASDAQ:ESPR)
Historical Stock Chart
From Mar 2024 to Apr 2024
Esperion Therapeutics (NASDAQ:ESPR)
Historical Stock Chart
From Apr 2023 to Apr 2024